BRCA2 and neoplasm: Interestingly, the majority of CDK12 mutations were shown to be mutually exclusive in BRCA1 and BRCA2 mutants, strongly indicating that CDK12 may act as an upstream effector in the same pathway in which BRCA1 and BRCA2 function as tumor suppressors45.